Top

Published in:

01-11-2014 | Original Article

Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip

Authors: Cristina d’Agostino, Pietro Romeo, Vito Lavanga, Salvatore Pisani, Valerio Sansone

Published in: Rheumatology International | Issue 11/2014

Abstract

There is no gold standard for treatment of bone marrow edema syndrome of the hip (BMESH). Usually, treatment is conservative, owing to the favorable and self-limiting prognosis. In musculoskeletal disorders, the effectiveness of extracorporeal shock wave therapy (ESWT) has been widely recognized and recent research supports its use in the treatment of the first stages of avascular osteonecrosis of the proximal femur and in other conditions where bone marrow edema is present. On this basis, we performed a prospective study to evaluate the effectiveness of ESWT in normalizing the symptoms and imaging features of BMESH. Twenty consecutive symptomatic patients underwent two treatments of high-energy ESWT and were followed-up at 2, 3 and 6 months, with a final clinical follow-up at mean 15.52 ± 1.91 months. Patients underwent magnetic resonance imaging of the hip and were evaluated according to the Harris hip score. The mean improvement in HHS over the course of the study was of 58.5 ± 14.9 points (p < 0.0001), and the mean edema area reduced from 981.9 ± 453.2 mm² pre-treatment to 107.8 ± 248.1 mm² at 6 months. ESWT seems to be a powerful, non-pharmacological tool that produces rapid pain relief and functional improvement and aids the normalization of the vascular and metabolic impairments which characterize BMESH.

Blum A, Roch D, Loeuille D, Lousi M, Bath T, Lecoeq S, Witte Y (2009) L’oedema meddullaire: definition, valeur diagnostique et pronostique. J Radiol 90:1789–1811PubMedCrossRef

Koo KH, Ahn IO, Kim R et al (1999) Bone marrow edema and associated pain in early stage osteonecrosis of the femoral head: prospective study with serial MR images. Radiology 213(3):715–722PubMedCrossRef

Koo KH, Ahn IO, Song HR, Kim SY, Jones JP Jr (2002) Increased perfusion of the femoral head in transient bone marrow edema syndrome. Clin Orthop Relat Res 402:171–175PubMedCrossRef

Hofmann S (2005) The painful bone marrow edema syndrome of the hip joint. Wien Klin Wochenschr 117(4):111–120PubMedCrossRef

Vande Berg BC, Lecouvert FE, Koutaissoff S, Simoni P, Malghem J (2008) Bone marrow edema of the femoral head and transient osteoporosis of the hip. Eur J Radiol 67:68–77PubMedCrossRef

Curtiss PH, Kincaid WE (1959) Transitory demineralization of the hip in pregnancy. J Bone Jt Surg Am 41-A:1327–1333

Plenk H Jr, Hofmann S, Eschberger J et al (1997) Histomorphology and bone morphometry of the bone marrow edema syndrome of the hip. Clin Orthop Relat Res 334:73–84PubMedCrossRef

Guardiano SA, Katz J, Schwartz AM, Brindle K, Curiel R (2004) Fracture complicating the bone marrow edema syndrome. J Clin Rheumatol 10:269–274PubMedCrossRef

Guerra JJ, Steinberg ME (1995) Distinguishing transient osteoporosis from avascular necrosis of the hip. J Bone Jt Surg Am 77:616–624

10.

Hayes CW, Balkissoon AA (1996) Magnetic resonance imaging of the musculoskeletal system. II. The hip. Clin Orthop 322:297–309PubMedCrossRef

11.

Radke S, Kenn W, Eulert J (2004) Transient bone marrow edema syndrome progressing to the avascular necrosis of the hip—a case report and a review of the literature. Clin Rheumatol 23:83–88PubMedCrossRef

12.

Radke S, Rader C, Kenn W, Kirschner S, Walther M, Eulert J (2003) Transient marrow edema syndrome of the hip: results after core decompression. A prospective MRI-controlled study in 22 patients. Arch Orthop Trauma Surg 123:223–227PubMed

13.

Aigner N, Petje G, Schneider W et al (2005) Bone marrow edema syndrome of the femoral head: treatment with the prostacyclin analogue iloprost vs core decompression. An MRI-controlled study. Wien Klin Wochenschr 117(4):130–135PubMedCrossRef

14.

Ogden JA, Tóth-Kischkat A, Schultheiss R (2001) Principles of shock wave therapy. Clin Orthop Relat Res 387:8–17PubMedCrossRef

15.

Wang FS, Yang KD, Kuo YR et al (2003) Temporal and spatial expression of bone morphogenetic proteins in extracorporeal shock wave-promoted healing of segmental defect. Bone 32:387–396PubMedCrossRef

16.

Wang CJ, Yang YJ, Huang CC (2011) The effects of shockwave on systemic concentrations of nitric oxide level, angiogenesis and osteogenesis factors in hip necrosis. Rheumatol Int 31(7):871–877PubMedCrossRef

17.

Mariotto S, Carcereri de Prati A, Cavalieri E et al (2009) Extracorporeal shock wave therapy in inflammatory diseases: molecular mechanism that trigger anti-inflammatory action. Curr Med Chem 16:2366–2372PubMedCrossRef

18.

Romeo P, d’Agostino MC, Lazzerini A, Sansone VC (2011) Extracorporeal shock wave therapy in pillar pain after carpal tunnel release: a preliminary study. Ultrasound Med Biol 37(10):1603–1608PubMedCrossRef

19.

Wang CJ, Wang FS, Huang CC, Yang KD, Weng LH, Huang HY (2005) Treatment for osteonecrosis of the femoral head: comparison of extracorporeal shock waves with core decompression and bone-grafting. J Bone Jt Surg Am 87(11):2380–2387CrossRef

20.

Wang CJ, Wang FS, Ko JY et al (2008) Extracorporeal shockwave therapy shows regeneration in hip necrosis. Rheumatology 47(4):542–546PubMedCrossRef

21.

Vulpiani MC, Vetrano M, Trischitta D et al (2012) Extracorporeal shock wave therapy in early osteonecrosis of the femoral head: prospective clinical study with long-term follow-up. Arch Orthop Trauma Surg 132(4):499–508PubMedCrossRef

22.

Tamma R, Dell’Endice S, Notarnicola A et al (2009) Extracorporeal shock waves stimulate osteoblastic activities. Ultrasound Med Biol 35(12):2093–2100PubMedCrossRef

23.

Van Der Jagt OP, Van Der Linden JC, Shaden W et al (2009) Unfocused extracorporeal shock wave therapy as potential treatment for osteoporosis. J Orthop Res 27(11):1528–1533PubMedCrossRef

24.

Gardeniers JWM (1992) A new international classification of osteonecrosis of the ARCO Committee on terminology and classification. J Jpn Orthop Assoc 66:18–20

25.

Ahlback S (1968) Osteoarthrosis of the knee. A radiographic investigation. Acta Radiol Diagn (Stockh) Suppl 277:7–72

26.

Ludwig J, Lauber S, Lauber HJ, Dreisilker U, Raedel R, Hotzinger H (2001) High-energy shock wave treatment of femoral head necrosis in adults. Clin Orthop Relat Res 387:119–126PubMedCrossRef

27.

Lin PC, Wang CJ, Yang KD, Wang FS, Ko JY, Huang CC (2006) Extracorporeal shockwave treatment of osteonecrosis of the femoral head in systemic lupus erythematosis. J Arthroplast 21(6):911–915CrossRef

28.

Gotte G, Amelio E, Russo S et al (2002) Short time non-enzymatic nitric oxide synthesis from L-arginine and hydrogen peroxide induced by shock waves treatment. FEBS Lett 520(1–3):153–155PubMedCrossRef

29.

Silverton S (1994) Osteoclast radicals. J Cell Biochem 56(3):367–373PubMedCrossRef

30.

Brandi ML, Hukkanen M, Umeda T et al (1995) Bidirectional regulation of osteoclasts function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA 92(7):2954–2958PubMedCrossRefPubMedCentral

31.

Hukkanen M, Platts LA, Lawes T et al (2003) Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia. Bone 32(2):142–149PubMedCrossRef

32.

Martini L, Giavaresi G, Fini M et al (2003) Effect of extracorporeal shock wave therapy on osteoblastlike cells. Clin Orthop Rel Res 413:269–280CrossRef

33.

Tam KF, Cheung Wing H, Lee K, Qin L, Leung KS (2005) Delayed stimulatory effect of low-intensity shockwaves on human periosteal cells. Clin Orthop Relat Res 438:260–265PubMedCrossRef

34.

Wang CJ, Yang KD, Ko JY, Huang CC, Huang HY, Wang FS (2009) The effects of shockwave on bone healing and systemic concentrations of nitric oxide (NO), TGF-beta1, VEGF and BMP-2 in long bone non-unions. Nitric Oxide 20(4):298–303PubMedCrossRef

35.

D’Agostino C, Romeo P, Amelio E, Sansone V (2011) Effectiveness of ESWT in the treatment of Kienböck’s disease. Ultrasound Med Biol 37(9):1452–1456PubMedCrossRef

36.

Szkopek K, Warming T, Neergaard K, Jørgensen HL, Christensen HE, Krogsgaard M (2012) Pain and knee function in relation to degree of bone bruise after acute anterior cruciate ligament rupture. Scand J Med Sci Sports 22(5):635–642PubMedCrossRef

37.

Boks SS, Vroegindeweij D, Koes BW, Hunink MG, Bierma-Zienstra SM (2006) Follow-up of occult bone lesions detected at MR imaging: systematic review. Radiology 238:853–862PubMedCrossRef

38.

Disch AC, Matziolis G, Perka C (2005) The management of necrosis-associated and idiopathic bone-marrow oedema of the proximal femur by intravenous iloprost. J Bone Jt Surg Br 87(4):560–564CrossRef

39.

Jager M, Tillman FP, Thornill TS et al (2008) Rationale for prostaglandin I2 in bone marrow edema—from theory to application. Arthritis Res Ther 10(5):R120PubMedCrossRefPubMedCentral

40.

Meizer R, Meraner D, Meizer E, Radda C, Landsiedl F, Aigner N (2009) Outcome of painful bone marrow edema of the femoral head following treatment with parenteral iloprost Indian. J Orthop 43(1):36–39

41.

Varenna M, Zucchi F, Binelli L, Failoni S, Gallazzi M, Sinigaglia L (2002) Intravenous pamidronate in the treatment of transient osteoporosis of the hip. Bone 31(1):96–101PubMedCrossRef

42.

Emad Y, Ragab Y, El-Shaarawy N, Rasker JJ (2012) Transient osteoporosis of the hip, complete resolution after treatment with alendronate as observed by MRI description of eight cases and review of the literature. Clin Rheumatol 31:1641–1647PubMedCrossRef

43.

Fabbriciani G, Pirro M, Manfredelli MR et al (2012) Transient osteoporosis of the hip: successful treatment with teriparatide. Rheumatol Int 32:1367–1370PubMedCrossRef

44.

Hofmann S, Engel A, Neuhold A, Leder K, Kramer J, Plenk H Jr (1993) Bone-marrow oedema syndrome and transient osteoporosis of the hip. An MRI-controlled study of treatment by core decompression. J Bone Jt Surg Br 75(2):210–216

45.

Calvo E, Fernandez-Yruegas D, Alvarez L (2000) Core decompression shortens the duration of pain in bone marrow oedema syndrome. Int Orthop 24:88–91PubMedCrossRefPubMedCentral

46.

Assaf AT, Smeets R, Riecke B, Weise E, Gröbe A, Blessmann M, Steiner T, Wikner J, Friedrich RE, Heiland M, Hoelzle F, Gerhards F (2013) Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res 33(9):3917–3924PubMed

Title: Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip
Authors: Cristina d’Agostino
Pietro Romeo
Vito Lavanga
Salvatore Pisani
Valerio Sansone
Publication date: 01-11-2014
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 11/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-014-2991-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2014

Effect of aquatic exercise on ankylosing spondylitis: a randomized controlled trial

Coexisting primary Sjögren’s syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome?

Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT

Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon

A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate

Fibromyalgia and non-celiac gluten sensitivity: a description with remission of fibromyalgia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page